간행물

대한간학회> Clinical and Molecular Hepatology(대한간학회지)

Clinical and Molecular Hepatology(대한간학회지) update

Clinical and Molecular Hepatology (CMH)

  • : 대한간학회
  • : 의약학분야  >  내과학
  • : KCI등재
  • : SCOPUS
  • : 연속간행물
  • : 계간
  • : 2287-2728
  • :
  • : 대한간학회지()→Korean Journal of Hepatology(2004~)→대한간학회지(2012~)

수록정보
수록범위 : 1권1호(1995)~25권4호(2019) |수록논문 수 : 4,590
Clinical and Molecular Hepatology(대한간학회지)
25권4호(2019년 12월) 수록논문
최근 권호 논문
| | | |

KCI등재 SCOPUS

1A leap for the journal: Clinical and Molecular Hepatology enters a new era

저자 : Yoon Jun Kim

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 4호 발행 연도 : 2019 페이지 : pp. 333-334 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재 SCOPUS

2Detect or not to detect very early stage hepatocellular carcinoma? The western perspective

저자 : Ju Dong Yang

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 4호 발행 연도 : 2019 페이지 : pp. 335-343 (9 pages)

다운로드

(기관인증 필요)

초록보기

Very early stage hepatocellular carcinoma (HCC) is defined as a single tumor with the largest diameter of the lesion measuring 2 cm or less according to Barcelona Liver Cancer staging system. Detection of very early stage HCC is clinically important as it confers an excellent prognosis with the 5-year survival rates over 60 to 80% after patients receive curative treatments. While diagnosing HCC at a very early stage is crucial, it is technically challenging and may come with the physical or psychosocial harms related to diagnostic tests. It is further complicated by the fact that patients with very early stage HCC are not prioritized for liver transplant (LT) in the United States organ allocation system. When LT-eligible patients present with an indeterminate lesion measuring between 1 and 2 cm on the multiphasic computed tomography or magnetic resonance imaging, clinicians often observe patients carefully until the lesion grows up to 2 cm so that patients can be eligible to receive a Model for End-Stage Liver Disease (MELD) exception score for HCC in the United States. The European guideline recommends a routine biopsy of such lesion. In conclusion, attempting to detect very early stage HCC is difficult to achieve and controversial. Clinicians should take into account of the risk and the benefit of diagnostic tests, LT candidacy of patients and the local organ allocation system. (Clin Mol Hepatol 2019;25:335-343)

KCI등재 SCOPUS

3Ultraselective conventional transarterial chemoembolization: When and how?

저자 : Shiro Miyayama

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 4호 발행 연도 : 2019 페이지 : pp. 344-353 (10 pages)

다운로드

(기관인증 필요)

초록보기

Ultraselective conventional transarterial chemoembolization (cTACE), defined as cTACE at the most distal portion of the subsubsegmental hepatic artery, is mainly performed for hepatocellular carcinoma (HCC) ≤5 cm. Distal advancement of a microcatheter enables injection of a larger volume of iodized oil into the portal vein in the limited area under non-physiological hemodynamics. As a result, the reversed portal flow into the tumor through the drainage route of the tumor that occurs when the hepatic artery is embolized is temporarily blocked. By adding gelatin sponge slurry embolization, both the hepatic artery and portal vein are embolized and not only complete necrosis of the tumor but also massive peritumoral necrosis can be achieved. Ultraselective cTACE can cure small HCCs including less hypervascular tumor portions and replace surgical resection and radiofrequency ablation in selected patients. (Clin Mol Hepatol 2019;25:344-353)

KCI등재 SCOPUS

4Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation?

저자 : Keun Soo Ahn , Koo Jeong Kang

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 4호 발행 연도 : 2019 페이지 : pp. 354-359 (6 pages)

다운로드

(기관인증 필요)

초록보기

There has been controversy regarding the first-line treatment modality for the patients who have small solitary hepatocellular carcinoma (HCC); radiofrequency ablation (RFA) or percutaneous ethanol injection (PEI), surgical hepatic resection (HR) and liver transplantation (LT). For selection of treatment modality of HCC, it should be considered of hepatic reservoir function as well as the tumor stage. If the liver function is good enough, HR may be the first choice regardless of the tumor size. However, recent studies comparing RFA with resection showed comparable outcome and similar survival rates. RFA, HR and LT provide good outcome for patients who have small HCCs. RFA would be desired in patients who have below 3.0 cm in size and low alpha-fetoprotein (<200 ng/mL). However, in small HCC with high tumor marker, HR should be considered. Better patient selection for the 'resection first' approach and early detection of recurrence can achieve better outcomes of the salvage LT strategy. Another benefit of resection first strategy is that it make possible to do enlist of LT for patients before recurrence at high risk of HCC recurrence after resection on the basis of pathologic aggressiveness, microvascular invasion and/or satellites nodule. They should be applied appropriately according to the tumor size, location, tumor markers and underlying liver parenchymal disease. (Clin Mol Hepatol 2019;25:354-359)

KCI등재 SCOPUS

5Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure

저자 : Tommaso Lorenzo Parigi , Maria Corina Plaz Torres , Alessio Aghemo

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 4호 발행 연도 : 2019 페이지 : pp. 360-365 (6 pages)

다운로드

(기관인증 필요)

초록보기

Despite the high efficacy of direct acting antivirals (DAAs) not all patients successfully clear hepatitis C virus infection, in fact, approximately 1-3% fail to reach a sustained virological response 12 weeks after end of treatment. DAA failures are characterized by advanced liver disease, specific genotypes/subtypes and resistance associated substitutions to the DAA class they have been treated with. Current European Association for the Study of the Liver guidelines recommend three therapeutic options for such patients. The first is a 12 week course of sofosbuvir (SOF), velpatasvir (VEL) and voxilaprevir (VOX), which has shown to be effective in 90-99% of patients and was granted A1 level recommendation. The second option, reserved for patients who have predictors of failure consists in 12 weeks regimen with glecaprevir (GLE) and pibrentasvir (PIB), effective in 90-97%. Finally, although not supported by published data, for especially difficult to treat patients there should theoretically be a benefit in prolonged combinations of SOF+GLE/PIB or SOF/VEL/VOX±ribavirin. This review presents the latest evidence from both clinical trials and real-life on such therapeutic strategies. (Clin Mol Hepatol 2019;25:360-365)

KCI등재 SCOPUS

6Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand

저자 : Ratchapong Laiwatthanapaisan , Pimsiri Sripongpun , Naichaya Chamroonkul , Arunee Dechaphunkul , Chirawadee Sathitruangsak , Siwat Sakdejayont , Chanon Kongkamol , Teerha Piratvisuth

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 4호 발행 연도 : 2019 페이지 : pp. 366-373 (8 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: Hepatitis B virus reactivation (HBVr) following chemotherapy (CMT) is well-known among hematologic malignancies, and screening recommendations are established. However, HBVr data in solid organ malignancy (SOM) patients are limited. This study aims to determine hepatitis B surface antigen (HBsAg) screening rates, HBV prevalence, and the rate of significant hepatitis caused by HBVr in SOM patients undergoing CMT.
Methods: Based on the Oncology unit's registration database from 2009-2013, we retrospectively reviewed records of all SOM patients ≥18 years undergoing CMT at Songklanagarind Hospital who were followed until death or ≥6 months after CMT sessions. Exclusion criteria included patients without baseline liver function tests (LFTs) and who underwent CMT before the study period. We obtained and analyzed baseline clinical characteristics, HBsAg screening, and LFT data during follow-up.
Results: Of 3,231 cases in the database, 810 were eligible. The overall HBsAg screening rate in the 5-year period was 27.7%. Screening rates were low from 2009-2012 (7.8-21%) and increased in 2013 to 82.9%. The prevalence of HBV among screened patients was 7.1%. Of those, 75% underwent prophylactic antiviral therapy. During the 6-month followup period, there were three cases of significant hepatitis caused by HBVr (4.2% of all significant hepatitis cases); all were in the unscreened group.
Conclusions: The prevalence of HBV in SOM patients undergoing CMT in our study was similar to the estimated prevalence in general Thai population, but the screening rate was quite low. Cases of HBVr causing significant hepatitis occurred in the unscreened group; therefore, HBV screening and treatment in SOM patients should be considered in HBV-endemic areas. (Clin Mol Hepatol 2019;25:366-373)

KCI등재 SCOPUS

7Incidence and risk factors of dysphagia after variceal band ligation

저자 : Saraswathi Arasu , Hammad Liaquat , Jaspreet Suri , Adam C. Ehrlich , Frank K. Friedenberg

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 4호 발행 연도 : 2019 페이지 : pp. 374-380 (7 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: There is a lack of data on long-term morbidity, particularly dysphagia, following endoscopic variceal band ligation (EVL). The aim of this study are to assess the incidence of dysphagia and variables associated with this complication after EVL.
Methods: We identified individuals who completed at least one session of EVL as their sole treatment for varices from August 2012 to December 2017. Included patients achieved “complete eradication” of varices not requiring further therapy. Patients ≥90 days from their last EVL session completed a modified version of the Mayo Clinic Dysphagia Questionnaire. Individuals with dysphagia were invited to undergo a barium esophagram. Patients with pre-EVL dysphagia were excluded.
Results: Of the patients, 68 possessed inclusion criteria, nine (13.2%) died and 20 (29.4%) were lost to follow up. For the remaining 39 (57.4%) patients, 23 were males, mean age of 61.7±8.6 years. The most common etiology of liver disease was hepatitis C virus (n=18; 46.2%). The median number of banding sessions was 2.0 (interquartile range [IQR], 1.0-4.0) with a median of 9.0 bands placed (IQR, 3.0-14.0). Twelve patients (30.8%) developed new-onset dysphagia post-EVL. In univariate analysis, pre-EVL MELD score and non-emergent initial banding were associated with long-term dysphagia. In a regression model adjusted for age, sex, number of bands, and use of acid suppression after EVL, no factor was independently associated with dysphagia (all P>0.05). No strictures were identified on subsequent esophageal evaluation.
Conclusions: Approximately 30% of patients developed new-onset, chronic dysphagia post-EVL. Incident dysphagia was associated with a non-emergent initial banding session. The mechanism for dysphagia remains unknown. (Clin Mol Hepatol 2019;25:374-380)

KCI등재 SCOPUS

8Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients

저자 : Kei Moriya , Tadashi Namisaki , Shinya Sato , Masanori Furukawa , Akitoshi Douhara , Hideto Kawaratani , Kosuke Kaji , Naotaka Shimozato , Yasuhiko Sawada , Soichiro Saikawa , Hiroaki Takaya , Koh Kitagawa ,

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 4호 발행 연도 : 2019 페이지 : pp. 381-389 (9 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: We previously reported the comparable efficacy of bi-monthly hepatic arterial infusion chemotherapy (B-HAIC) to that of sorafenib chemotherapy for the treatment of advanced hepatocellular carcinoma (aHCC) in patients with compensated cirrhosis. In this study, we demonstrate the efficacy of B-HAIC in patients with decompensated cirrhosis.
Methods: Forty-five patients with aHCC refractory to transcatheter arterial chemo-embolization (TACE) were treated with B-HAIC and were divided into two groups according to hepatic functional reserve (Child-Pugh grade). Overall survival period, treatment response, and adverse events in each group were analyzed.
Results: Efficacy and disease control rates in the Child-Pugh B group (n=24; 21% and 71%, respectively) were not significantly impaired compared the Child-Pugh A group (n=21; 38% and 67%, respectively). Median survival time and survival rate at 12 months in the Child-Pugh B group were 422 days and 58.3%, respectively, whereas those in the Child- Pugh A group were 567 days and 70.8%, respectively. Importantly, the hepatic functional reserve of patients did not worsen in either group during the treatment period. Furthermore, the occurrence rate of adverse events leading to discontinuation of anti-tumor treatment was not significantly increased in the Child-Pugh B group.
Conclusions: Given the preservation of hepatic functional reserve afforded by B-HAIC chemotherapy in patients with decompensated cirrhosis, B-HAIC might be an acceptable alternative strategy for aHCC patients who do not respond to TACE. (Clin Mol Hepatol 2019;25:381-389)

KCI등재 SCOPUS

9Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B

저자 : Haneulsaem Shin , Yeon Woo Jung , Beom Kyung Kim , Jun Yong Park , Do Young Kim , Sang Hoon Ahn , Kwang-hyub Han , Yeun-yoon Kim , Jin-young Choi , Seung Up Kim

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 4호 발행 연도 : 2019 페이지 : pp. 390-399 (10 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: A risk prediction model for the development of hepatocellular carcinoma (HCC) from indeterminate nodules detected on computed tomography (CT) (RadCT score) in patients with chronic hepatitis B (CHB)-related cirrhosis was proposed. We validated this model for indeterminate nodules on magnetic resonance imaging (MRI).
Methods: Between 2013 and 2016, Liver Imaging Reporting and Data System (LI-RADS) 2/3 nodules on MRI were detected in 99 patients with CHB. The RadCT score was calculated.
Results: The median age of the 72 male and 27 female subjects was 58 years. HCC history and liver cirrhosis were found in 47 (47.5%) and 44 (44.4%) patients, respectively. The median RadCT score was 112. The patients with HCC (n=41, 41.4%) showed significantly higher RadCT scores than those without (median, 119 vs. 107; P=0.013); the Chinese university-HCC and risk estimation for HCC in CHB (REACH-B) scores were similar (both P>0.05). Arterial enhancement, T2 hyperintensity, and diffusion restriction on MRI were not significantly different in the univariate analysis (all P>0.05); only the RadCT score significantly predicted HCC (hazard ratio [HR]=1.018; P=0.007). Multivariate analysis showed HCC history was the only independent HCC predictor (HR=2.374; P=0.012). When the subjects were stratified into three risk groups based on the RadCT score (< 60, 60-105, and >105), the cumulative HCC incidence was not significantly different among them (all P>0.05, log-rank test).
Conclusions: HCC history, but not RadCT score, predicted CHB-related HCC development from LI-RADS 2/3 nodules. New risk models optimized for MRI-defined indeterminate nodules are required. (Clin Mol Hepatol 2019;25:390-399)

KCI등재 SCOPUS

10An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection

저자 : Youn Jae Lee , Jeong Heo , Do Young Kim , Woo Jin Chung , Won Young Tak , Yoon Jun Kim , Seung Woon Paik , Eungeol Sim , Susila Kulasingam , Rohit Talwani , Barbara Haber , Peggy Hwang

발행기관 : 대한간학회 간행물 : Clinical and Molecular Hepatology(대한간학회지) 25권 4호 발행 연도 : 2019 페이지 : pp. 400-407 (8 pages)

다운로드

(기관인증 필요)

초록보기

Background/Aims: In the Republic of Korea, an estimated 231,000 individuals have chronic hepatitis C virus (HCV) infection. The aim of the present analysis was to evaluate the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) administered for 12 weeks in Korean patients who were enrolled in international clinical trial phase 3 studies.
Methods: This was a retrospective, integrated analysis of data from patients with HCV genotype (GT) 1b infection enrolled at Korean study sites in four EBR/GZR phase 3 clinical trials. Patients were treatment-naive or had previously failed interferon-based HCV therapy, and included those with human immunodeficiency virus coinfection or Child- Pugh class A cirrhosis. All patients received EBR 50 mg/GZR 100 mg once daily for 12 weeks. The primary endpoint was sustained virologic response at 12 weeks after completion of therapy (SVR12, HCV RNA < 15 IU/mL).
Results: SVR12 was achieved by 73 of 74 (98.6%) patients. No patients had virologic failure and one discontinued from the study after withdrawing consent. SVR12 rates were uniformly high across all patient subgroups. A total of 16 patients had nonstructural protein 5A resistance-associated substitutions at baseline (16/73, 22%), all of whom achieved SVR12. Adverse events (AEs) reported in >5% of patients were fatigue (6.8%), upper respiratory tract infection (5.4%), headache (5.4%), and nausea (5.4%). Thirteen patients (17.6%) reported drug-related AEs, two serious AEs occurred, and two patients discontinued treatment owing to an AEs.
Conclusions: In this retrospective analysis, EBR/GZR administered for 12 weeks was well-tolerated and highly effective in Korean patients with HCV GT1b infection. (Clin Mol Hepatol 2019;25:400-407)

12
권호별 보기
가장 많이 인용된 논문

(자료제공: 네이버학술정보)

가장 많이 인용된 논문
| | | |
1연안해역에서 석유오염물질의 세균학적 분해에 관한 연구

(2006)홍길동 외 1명심리학41회 피인용

다운로드

2미국의 비트코인 규제

(2006)홍길동심리학41회 피인용

다운로드

가장 많이 참고한 논문

(자료제공: 네이버학술정보)

가장 많이 참고한 논문

다운로드

2미국의 비트코인 규제

(2006)홍길동41회 피인용

다운로드

해당 간행물 관심 구독기관

한국보건의료연구원 아산의학도서관 청운대학교 중앙대학교(서울) 남부대학교
 9
 9
 7
 6
 6
  • 1 한국보건의료연구원 (9건)
  • 2 아산의학도서관 (9건)
  • 3 청운대학교 (7건)
  • 4 중앙대학교(서울) (6건)
  • 5 남부대학교 (6건)
  • 6 동아대학교 (4건)
  • 7 상지대학교 (4건)
  • 8 충남대학교 (4건)
  • 9 진주보건대학교 (3건)
  • 10 성신여자대학교 (3건)

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기